NPC Member Companies Respond to COVID-19 Pandemic

COVID-19. Photo Credit: CDC

This page will be updated regularly. For additional information about COVID-19, visit the Centers for Disease Control and Prevention.

Updated June 17, 2020

The scale and severity of the COVID-19 pandemic is becoming more clear: we are facing a challenge – a public health challenge, a research challenge, an economic challenge – like none of us have seen in our lifetime. Given the immense impact, it is important for all health care stakeholders to come together to change the course of this disease and support those who are most affected.

The National Pharmaceutical Council (NPC) is proud of the commitment and efforts of our member companies as they fight COVID-19 by supporting innovative clinical research, ensuring continuous patient access to needed medications and providing resources to vulnerable communities globally.

Read more below about how our members are responding to both the public health threat and the economic crisis.

  • AbbVie
    AbbVie is working with health authorities and research institutions around the globe on clinical research related to COVID-19. Abbvie employees with relevant scientific, health care and other critical expertise who volunteer in times of pandemic crisis will continue to receive full pay and benefits during their temporary service period. AbbVie has donated $35 million to help support underserved communities and health care systems working to address the impact of the COVID-19 global pandemic. Learn more about specific actions on AbbVie’s Coronavirus Response page.
  • Amgen
    Amgen is partnering to develop therapies to treat or prevent COVID-19. The company is also supporting local emergency response efforts and patient-focused organizations. Amgen updates, public health resources and patient information can be found at Amgen’s COVID-19 Information Center site.
  • Astellas
    Astellas Pharma US and the Astellas Global Health Foundation are each expanding support for global and local communities fighting COVID-19 to meet the urgent demand for resources to help patients, health care workers and first responders. To learn more about Astellas’ efforts, click here.
  • AstraZeneca
    AstraZeneca donated 9 million face masks to support health care workers around the world fighting the virus. Additionally, the company is accelerating the development of diagnostic tests and discovery of potential treatments to prevent COVID-19. More details can be found in AstraZeneca’s Update on COVID-19.
  • Bayer HealthCare Pharmaceuticals
    Bayer is providing governments and health authorities with needed medication, including chloroquine phosphate, medical supplies and resources. Most recently, the company established a testing laboratory in Berlin with the capacity to conduct 1,000 additional SARS-CoV-2 tests per day. Stay up to date with Bayer’s latest actions on its Commitment During Coronavirus Pandemic page.
  • Biogen
    The Biogen Foundation is providing medical equipment and supplies to areas most in need, including Massachusetts, North Carolina and Italy. Updates and more information can be found at Biogen’s COVID-19 Information Center.
  • Boehringer Ingelheim
    Boehringer Ingelheim has made financial donations for emergency aid and is conducting cutting-edge computational screenings of compounds from its former antiviral research against the SAR-CoV2. Learn more about Boehringer Ingelheim’s full COVID-19 clinical and community response here.
  • Bristol-Myers Squibb
    Bristol Myers Squibb (BMS) and the Bristol Myers Squibb Foundation are providing financial support and needed products at global and local levels to support front-line health care workers, patients and community-based groups that serve vulnerable populations. BMS expanded its existing patient support programs to help eligible unemployed patients in the U.S. who have lost their health insurance due to the COVID-19 pandemic. The expanded program offers access to BMS medicines for free, including some of the company’s most widely prescribed products, as well as those prescribed via telehealth services. For more details on BMS’s response to COVID-19, please visit here.
  • Lilly
    Eli Lilly and Company and AbCellera are partnering to co-develop antibodies for the potential treatment and prevention of COVID-19. Additionally, Lilly scientists are partnering with the Indiana State Department of Health, with support from the Food and Drug Administration, to accelerate testing in Indiana for SARS-CoV-2, the virus that causes COVID-19. Read more about this and the other actions Lilly is taking on its Global COVID-19 Response page.
  • Genentech
    Genentech is directing resources to assist with food and housing for vulnerable communities. The company is also currently enrolling patients to test the efficacy of the drug Actemra® in severe COVID-19. Read more about Genentech’s effort on its COVID-19 response page.
  • Gilead Sciences
    Gilead created an expanded access program for critical patients who need the organization’s investigational coronavirus medication, remdesivir, who are unable to enroll in ongoing clinical trials. See the other efforts Gilead is undertaking on its Ongoing Response to COVID-19 page.
  • Intercept Pharmaceuticals
    Intercept is working to ensure there are no supply chain disruptions for patients who rely on its medication. See the company’s full response statement.
  • Ipsen
    Ipsen is supporting the Institute Pasteur’s activities to accelerate clinical research of COVID-19. Read the company’s COVID-19 update here. Alongside AAAS/Science, Fondation Ipsen will be hosting an international webinar open to the public on April 15, 2020, called “Ask the Experts about Coronavirus.” 
  • Johnson & Johnson
    Johnson & Johnson announced the selection of a lead COVID-19 vaccine candidate, the significant expansion of the existing partnership between the Janssen Pharmaceutical Companies of Johnson & Johnson and the Biomedical Advanced Research and Development Authority (BARDA), and the rapid scaling of its manufacturing capacity with the goal of supplying more than one billion doses on a not-for-profit basis for emergency pandemic use. Its response to the outbreak also includes working with global partners to identify a treatment that could provide immediate relief to the pandemic.  
  • Mallinckrodt
    Mallinckrodt received approval from Health Canada to begin pilot trials of its inhaled nitric oxide therapy for COVID-19. Learn more about the company’s innovative developments.
  • Merck
    Merck has partnered with the Melinda and Bill Gates Foundation and a group of other life-science companies to accelerate the development of a COVID-19 vaccine. In addition, the company has donated masks, responded to the call for skilled volunteers and supported local relief efforts. Read about Merck’s full response to the virus.  
  • Novartis
    Novartis donated millions of hydroxychloroquine tablets for use in COVID-19 clinical trials and use by the U.S. Department of Health and Human Services. View the organization’s response.
  • Pfizer
    Pfizer shared its five-point plan to help combat COVID-19, including sharing technical tools and offering manufacturing capacity to be able to speed production and delivery of coronavirus therapies and vaccines to patients. Read more about the company’s efforts on its coronavirus response page.
  • Sarepta Therapeutics
    Sarepta is encouraging patients with questions about its medication, clinical trials and COVID-19 to utilize the company’s SareptAssist program to seek guidance.
  • Spark
    Spark Therapeutics is continuing to run its patient assistance programs to ensure patients will have uninterrupted access to vital clinical information and financial assistance options. Learn more about the company’s program.
  • Takeda
    Takeda is rapidly developing a plasma-based therapy that shows promise in treating high-risk individuals with COVID-19. Learn about Takeda’s full response to coronavirus.
  • Teva
    Teva has donated more than 10 million doses of hydroxychloroquine sulfate tablets through wholesalers to hospitals across the U.S. The company is also working with governments throughout the country and collaborating on additional ways to address national need. View the company’s commitments.
  • UCB, Inspired by patients. Driven by science.
    UCB is contributing to basic research and treatment development for COVID-19, offering expertise to increase local testing capabilities where the company has lab facilities, and supporting locally and globally through donations as well as direct assistance to patients and partners. Read more on how UCB is playing its part and its latest response.